Several immunotherapeutic approaches have been developed targeting BCMA in multiple myeloma, including mAbs, T-cell bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapies, and antibody–drug conjugates (ADC). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.